Drugs / MELITAC 12.1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01585350 | Oct 2012 → Jul 2014 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1 | NCT00977145 | Nov 2009 → Oct 2012 | melanoma | Craig L Slingluff, Jr | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01264731 Comparator | Jan 2011 → Jun 2012 | melanoma | University of Virginia | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MELITAC 12.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01585350 ↗ |
| Modality | Vaccine | “systemic vaccination with MELITAC 12.1” NCT00977145 ↗ |
| Route | Other | “The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.” NCT00977145 ↗ |
| Route | Subcutaneous | “The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.” NCT00977145 ↗ |